Stock Ratings / Health Care / CLDX / dividends

NEOG (52) NTLA (33) QDEL (30) ORKA (53) ⌘ Pro Terminal →

Celldex Therapeutics Inc. (CLDX) Dividend Safety Gauge & 10-Year DRIP Compounder

$29.89 +0.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Celldex Therapeutics Inc. (CLDX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.35B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLDX)Realized 20D OHLCV Swing Band: ±9.6%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLDX)

✓Walkthrough of CLDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.09%📐 HORIZONTAL RANGE

2026-10-30O $29.70H $30.27L $29.20C $29.89VOL 870.8K

RES: $51.57SUP: $26.50SMA50: $34.06SMA200: $32.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLDX Butterfly Map → + Track CLDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLDX)

Health Care Rank #603 of 1016 ⚔️ NEOG vs CLDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLDX vs. NEOG, NTLA, QDEL, ORKA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Celldex Therapeutics Inc. (CLDX) ranks #603 by composite RQD confidence (41/100, grade D-) and #231 by equity capitalization ($2.35B). Within this direct 5-issuer industry benchmark cohort, CLDX leads on earnings valuation at N/A trailing P/E, while NEOG leads on capital efficiency and profitability with -0.6% ROIC and 46.9% gross margin. ORKA currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with CLDX at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLDX ACTIVE Celldex Therapeutics Inc.	D-	41/100	—	87.1%	-35.0%	+0.78%	$2.35B	Benchmark Subject
NEOG Neogen Corporation	D+	52/100	—	46.9%	-0.6%	+1.16%	$2.68B	/neog-vs-cldx →
NTLA Intellia Therapeutics Inc.	E	33/100	—	—	-35.0%	-0.68%	$1.85B	/ntla-vs-cldx →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-cldx →
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	+0.71%	$6.40B	/orka-vs-cldx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000744218

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celldex Therapeutics Inc. (CLDX) reported GAAP revenue of $1.5M (-78.0% vs. FY2024 revenue of $7.0M , and -77.6% cumulative change since FY2023) , GAAP net income of -$258.8M, operating cash flow of -$210.9M, and free cash flow of -$213.7M (-33.8% YoY). On the balance sheet, CLDX closed FY2025 with $583.0M in total assets against $0 in total debt (Altman Z-Score: 20.25, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.5M	-$258.8M	-$210.9M	-$213.7M	$583.0M	—
FY2024 (FY)	2024-12-31	$7.0M	-$157.9M	-$157.8M	-$159.7M	$792.3M	—
FY2023 (FY)	2023-12-31	$6.9M	-$141.4M	-$107.3M	-$107.3M	—	—

3. CLDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Celldex Therapeutics Inc. (NASDAQ: CLDX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $29.89 (+0.78% 1D, market cap $2.35B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLDX ranks #603 in composite RQD confidence.

How does CLDX compare to NEOG and NTLA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), CLDX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 87.1%, and ROIC of -35.0%. By comparison, NEOG (Neogen Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -0.6%, cap $2.68B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, CLDX leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLDX?

Per CLDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000744218), Celldex Therapeutics Inc. generated $1.5M in revenue (-78.0% YoY), -$258.8M in net income, and -$213.7M in free cash flow against $583.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLDX trading relative to its 50-day, 200-day, and 52-week technical levels?

CLDX last traded at $29.89 (+0.78% on volume of 918,886 shares), positioning the stock -12.24% below its 50-day simple moving average ($34.06) and -8.45% below its 200-day simple moving average ($32.65). Across its 52-week range of $22.10 to $45.14, CLDX sits at the 33.8% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($27.02 to $32.76).

CLDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CLDX pay a dividend and is it safe?

Celldex Therapeutics Inc. (CLDX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CLDX RQD Cockpit CLDX 12M Forecast CLDX Earnings & Move CLDX Dividends & DRIP CLDX Insiders & 13F CLDX Whale Options CLDX Profit Sankey CLDX News & Why